Importance For more than a decade, sorafenib has been the only systemic treatment option
for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over …

Harnessing the immune system to treat cancer through inhibitors of CTLA4 and PD-L1 has
revolutionized the landscape of cancer. Rational combination strategies aim to enhance the …

Human malignancies are one of the major health-related issues though out the world and
anticipated to rise in the future. The development of novel drugs/agents requires a huge …

Preclinical and clinical antiangiogenic approaches, with multiple side effects such as
resistance, have not been proved to be very successful in treating tumor blood vessels …

Immune checkpoint inhibitor therapy has revolutionized the field of cancer immunotherapy.
Even though it has shown a durable response in some solid tumors, several patients do not …

In recent decades, dysregulation of proteases and atypical proteolysis have become
increasingly recognized as important hallmarks of cancer, driving community-wide efforts to …

Tumor angiogenesis induces local hypoxia and recruits immunosuppressive cells, whereas
hypoxia subsequently promotes tumor angiogenesis. Immunotherapy efficacy depends on …

Leakage and compression of blood vessels may result in deprivation of blood flow to a large
number of tumor tissues, which can lead to tumor hypoxia. Hypoxia induces an increase in …

Cancer is a complex group of diseases that constitute the second largest cause of mortality
worldwide. The development of new drugs for treating this disease is a long and costly …

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, of which
the occurrence and development involve a variety of pathophysiological processes, such as …